论文部分内容阅读
目的评价Hyper-CVAD/MA中的MA(甲氨蝶呤+阿糖胞苷)+G-CSF方案动员恶性淋巴瘤患者造血干细胞的有效性。方法回顾性分析本院2006年1月至2010年5月采用MA+G-CSF方案动员11例侵袭性非霍奇金淋巴瘤(NHL)患者造血干细胞的效果、安全性。结果 11例患者都1次采集成功。所采集的单个核细胞(MNC)总数(4.23±1.63)×108/kg,CD34+细胞总数(5.45±4.63)×106/kg,达到移植所需的干细胞数量。动员过程毒副反应不大,易于控制,患者能够耐受。移植后除2例复发死亡外,7例完全缓解,2例部分缓解。结论 MA+G-CSF方案动员恶性淋巴瘤患者造血干细胞安全、有效、易于操作、又可起到移植前体内净化的作用。
Objective To evaluate the effectiveness of MA (methotrexate + cytarabine) + G-CSF regimen in mobilizing hematopoietic stem cells from patients with malignant lymphoma in Hyper-CVAD / MA. Methods The effect and safety of mobilization of hematopoietic stem cells from 11 patients with aggressive non-Hodgkin’s lymphoma (NHL) by MA + G-CSF regimen from January 2006 to May 2010 in our hospital were retrospectively analyzed. Results All the 11 patients were successfully collected one time. The total number of mononuclear cells (MNC) collected (4.23 ± 1.63) × 108 / kg and the total number of CD34 + cells (5.45 ± 4.63) × 106 / kg reached the number of stem cells needed for transplantation. Toxic side effects of mobilization process is not easy to control, patients can tolerate. In addition to 2 cases of recurrent death after transplantation, 7 patients were completely relieved, 2 patients partially relieved. Conclusion MA + G-CSF regimen is safe, effective and easy to operate for hematopoietic stem cells in patients with malignant lymphoma. In addition, hematopoietic stem cells can be purified before MA transplantation.